The federal Project Grant award R01DK137997, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is providing $340,747.00 to Vanderbilt University Medical Center (VUMC) to conduct research on reducing iatrogenic hyperinsulinemia in type 1 diabetes patients. The research aims to investigate the cardiometabolic benefits of using insulin adjunctive therapy to lower peripheral insulin levels in this patient population, compared to individuals with glucokinase maturity onset diabetes of the young (GCK-MODY) and those without diabetes. The study will examine the effects on nitric oxide bioavailability, insulin sensitivity, and thrombotic potential. This small, mechanistic pilot study is expected to provide key data to inform the development of larger clinical trials evaluating insulin adjunctive therapy for improving cardiovascular disease outcomes in type 1 diabetes.
Generated 3/4/25, 2:34 AM